Clozapine (CLZ) is a "gold standard" drug for managing treatment-resistant schizophrenia (TRS), who do not respond adequately to first-line antipsychotics. Despite its efficacy with TRS, the use of ...
For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant schizophrenia, and the only one it recognizes as reducing the risk of suicide. This ...
Patients with schizophrenia will no longer have to provide blood test results before filling their clozapine prescription, according to the US Food and Drug Administration (FDA). HealthDay News — The ...
Clozapine remains the antipsychotic agent of choice for treatment‐resistant schizophrenia; however, its efficacy is frequently hampered by adverse effects such as hypersalivation and sialorrhea. These ...
Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That's what a joint meeting of two FDA advisory committees will discuss on Tuesday. Risk management requirements for the ...
Although clinicians and advocates applauded the US Food and Drug Administration (FDA)’s recent decision to discontinue a risk management and evaluation program for the antipsychotic clozapine, some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results